SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Promising Safety, Tolerability and Efficacy Results from Morria Biopharmaceuticals Plc' MRX-4 Phase II Study in Allergic Rhinitis to be Presented at the upcoming EAACI Congress